Parexel International, a Boston-based global CRO, has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a provider of specialized pharmacovigilance services.
Pharmacovigilance refers to the collection, detection, assessment, monitoring and prevention of adverse effects with pharmaceutical products. The acquisition is expected to close in early April, subject to closing conditions.
QSI was established in 2004, and delivers pharmacovigilance services including individual case safety report processing, brand physician activities, affiliate support, aggregate report writing, literature reviews and signal detection. The company serves pharmaceutical, medical device and consumer clients across the globe, and has approximately 900 employees.
Josef von Rickenbach, chairman and CEO of Parexel, said, "The acquisition of QSI will strengthen our capabilities in the growing field of outsourced safety management solutions, or pharmacovigilance. It will help us to create greater scale in this service area, and thereby enable us to provide a more comprehensive, efficient and economical solution to clients around the world. Combined with the existing post-approval and regulatory strengths of Parexel, this acquisition will support the expansion of our pharmacovigilance services onto a broader platform."
The QSI business will be integrated into Parexel's Peri/Post-Approval Services group, which is part of the CRS segment. It also is expected to have strong synergies with Parexel's Regulatory Outsourcing Services business within the Parexel Consulting segment.
The purchase will be funded with existing cash.